Acorah Software Products - Accounts Production 16.5.460 false true false true No description of principal activity 16 January 2024 31 January 2025 31 January 2025 15416039 Mr Manuel Loureda Mr Manuel Loureda iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 15416039 2024-01-15 15416039 2025-01-31 15416039 2024-01-16 2025-01-31 15416039 frs-core:CurrentFinancialInstruments 2025-01-31 15416039 frs-bus:PrivateLimitedCompanyLtd 2024-01-16 2025-01-31 15416039 frs-bus:FilletedAccounts 2024-01-16 2025-01-31 15416039 frs-bus:Micro-entities 2024-01-16 2025-01-31 15416039 frs-bus:AuditExempt-NoAccountantsReport 2024-01-16 2025-01-31 15416039 frs-bus:Director1 2024-01-16 2025-01-31 15416039 frs-bus:CompanySecretary1 2024-01-16 2025-01-31
Registered number: 15416039
Pharmaeng Solutions Ltd
Unaudited Financial Statements
For the Period 16 January 2024 to 31 January 2025
Balance Sheet
Registered number: 15416039
31 January 2025
£
Fixed assets 3,744
Current assets 16,698
Creditors: Amounts Falling Due Within One Year (6,691 )
NET CURRENT ASSETS 10,007
TOTAL ASSETS LESS CURRENT LIABILITIES 13,751
Accruals and deferred income (299 )
NET ASSETS 13,452
CAPITAL AND RESERVES 13,452

Notes

1. General Information
Pharmaeng Solutions Ltd is a private company, limited by shares, incorporated in England & Wales, registered number 15416039 . The registered office is 24 Lakeland Crescent, Alwoodley, Leeds, LS17 7PR.
2. Average Number of Employees
Average number of employees, including directors, during the period was: 1
1
For the period ending 31 January 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The member has not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared in accordance with the micro-entity provisions and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
On behalf of the board
Mr Manuel Loureda
Director
1st October 2025